The MAPK pathway and the role of BRAF and MEK inhibitors. | Download Scientific Diagram
Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms | Bentham Science
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review - ScienceDirect
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review | JACC: CardioOncology
Combined BRAF and MEK Inhibition for Patients with Advanced Melanoma
Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4 | IntechOpen
A combined therapy improves survival in patients with metastatic melanoma | Hospital Clínic Barcelona
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma | Nature Reviews Clinical Oncology
Clinical Development of BRAF plus MEK Inhibitor Combinations: Trends in Cancer
IJMS | Free Full-Text | Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
Figure 1 from Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. | Semantic Scholar
Cancers | Free Full-Text | Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
Biomarkers May Predict Response to BRAF and MEK inhibitors in Malignant Melanoma – OncoPrescribe
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management - ScienceDirect
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma - ScienceDirect
BRAF/MEK Inhibitor Combinations Impressive in Melanoma Trials - The ASCO Post
MEK inhibitors for the treatment of non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines - Annals of Oncology
BRAF Alterations in Primary Brain Tumors - Stefania Maraka - Discovery Medicine
Systemic treatment for BRAF-mutant melanoma: where do we go next? - The Lancet Oncology
Cancers | Free Full-Text | Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
BRAF inhibitors
Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway | Personalized Medicine in Oncology
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? - ScienceDirect
